← Back to Search

Other

BI 1819479 for Pulmonary Fibrosis

Phase 2
Recruiting
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients ≥40 years old at the time of signed informed consent.
Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

"This trial is looking for adults over 40 with idiopathic pulmonary fibrosis (IPF) who are not currently on treatment or have been on stable treatment for at least 3 months. The study

Who is the study for?
Adults over 40 with idiopathic pulmonary fibrosis (IPF) can join this trial. They must have a certain level of lung function and if they're on IPF treatment, it needs to be stable for at least 3 months. Women who can have children and men whose partners can, must use effective birth control.
What is being tested?
The study tests BI 1819479's effect on lung function in IPF patients. Participants are randomly assigned to one of four groups: three different doses of the drug or a placebo, taken for up to a year with regular health checks and breathing tests.
What are the potential side effects?
While specific side effects aren't listed here, participants' health is closely monitored for any unwanted effects from either the actual drug or the placebo during their numerous visits and calls throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 40 years old or older.
Select...
I have been diagnosed with Idiopathic Pulmonary Fibrosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: BI 1819479 medium dose treatment groupExperimental Treatment1 Intervention
Group II: BI 1819479 low dose treatment groupExperimental Treatment1 Intervention
Group III: BI 1819479 high dose treatment groupExperimental Treatment1 Intervention
Group IV: Placebo groupPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BI 1819479
2022
Completed Phase 1
~170

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,549 Previous Clinical Trials
14,401,016 Total Patients Enrolled
52 Trials studying Idiopathic Pulmonary Fibrosis
47,641 Patients Enrolled for Idiopathic Pulmonary Fibrosis
~200 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top